Zolt 29.41 Rating:Short term buy/trade

Zolt looks poised to run again. Would set tight stop. Target 33-36.

LBIX Earnings Dissapoint as Expected

Stock rebounded off its lows of 2.50 to close above 2.70. As we mentioned twice before when the stock was at 3.13 and 2.90 no reason to buy ahead of the earnings. Tempted to take a small position at these levels but instead will wait until the technicals "say" buy.

ESCL 7.50 Rating:Sell

ESCL is going to retest its old lows after the bad news sets in. Target 3.00-4.00

PTIX 7.10 Rating:Buy short term target 9.00

Great Cash position. Coming off its support. Looks good till 9.00

IRIX 10.17 Speculative Buy/Watchlist

IRIX makes therapeutic-based laser systems and delivery devices. With a market cap of under 100 million this stock has room to grow. Great cash position and book value is at $4.76 a share. That being said, technically this stock is a mess. Would look to enter in the 8's. or a breakout above 12.

PEIX & ERS shorts

PEIX- After recommending this one short at 34.00 it hit an intraday low of 25, now back at 31 would cover and wait to short again.


ERS- We take 20% profit and cover. Look to short again after a rebound

LBIX Earnings Watch

LBIX to announce earnings tommorrow. Stock closed today at 2.90. Although it was up .30 cents today, the risk of holding before earnings is not warranted. Put this one on your watchlist and either buy the good news or sit on the sidelines and get in big below two dollars. Long term this company is set to grow. Short term b/c of higher marketing cost & slower season earnings could dissapoint.

With so much of the volume right at the two dollar level, a break of two would cause significant damage to this stock.. Maybe an entry as low as 1.00-1.50 could be possible.

Good news on this stock, LBIX will be up 30-50%.

IDSA 6.38 Rating Buy 12 month target 13.75

Good entry here after the parabolic rise. Chart looks good.

GTW Gateway 1.72 Rating Strong Buy Target 5.00

Gtw- Insiders buying big at these levels. Never discount a Brand name. There is Brand Equity that investors have discounted too much. Target 5.00

Sepr Xopenex news.. Huge

Second paragraph. 1.1 billion

2006 MAY 25 - (NewsRx.com) -- Decision Resources, Inc., a research and advisory firm focusing on pharmaceutical and health care issues, finds that compliance to a clean air treaty by the United States Food and Drug Administration (FDA) will force leading metered-dose inhalers containing ozone-depleting propellants off the U.S. asthma treatment market by the end of 2008. "Because all current generic versions of inhaled albuterol contain ozone-depleting chlorofluorocarbon (CFC) propellants, all generics will be removed from the U.S. market in 2008, leaving only higher-priced branded albuterol propelled with hydrofluoroalkane," said Vickie Lai, analyst at Decision Resources. "As a result, the albuterol market in the U.S. will become branded only, leading to $1 billion in major market sales for Ventolin and Proventil in 2014-more than doubling their sales totals from 2004."

The report also finds that more physicians will turn to levalbuterol as an alternative to albuterol, generating $1.1 billion in sales in the seven major markets for Sepracor's Xopenex (levalbuterol) in 2014.

"Because all current generic versions of inhaled albuterol contain ozone-depleting chlorofluorocarbon (CFC) propellants, all generics will be removed from the U.S. market in 2008, leaving only higher-priced branded albuterol propelled with hydrofluoroalkane," said Vickie Lai, analyst at Decision Resources. "As a result, the albuterol market in the U.S. will become branded only, leading to $1 billion in major market sales for Ventolin and Proventil in 2014-more than doubling their sales totals from 2004."

LBIX Recommendation(Hold)

Although buying below 2.50 is a good entry, until earnings are out I wouldn't buy a huge position. This company has moved from under a dollar to over four in one year. Its now giving back its gains. 50% would put the retracement around 2.00-2.20.. With some bad news on the earnings front 1.50 is possible.

SEPR News After the Volume

Sepracor says drug quickly boosts lung function
Wed May 24, 2006 6:35 PM ET
LOS ANGELES, May 24 (Reuters) - Sepracor Inc. (SEPR.O: Quote, Profile, Research) on Wednesday said its experimental drug for smoker's cough proved as effective in a late-stage clinical trial as GlaxoSmithKline Plc's (GSK.L: Quote, Profile, Research) long-acting bronchodilator medicine Serevent, but took effect far more quickly.

Here is some good news. Not surprising, just like we reported a week ago, something is going on at sepr.

Volume again was huge. Buying interest in the June 6o calls is strong.

SNDA: 14.85 Strong Buy Target 25

SNDA- Chart looks great. Macd about to go green. Would buy on any dips.

CEDC 33.00 Rating: Strong Buy

Cedc: The story is Poland is blocking CEDC's purchase of a local vodka maker. Understandably you would imagine this would hurt the stock price. Although 2006 estimates haven't taken into account any acquisitions, the 2007 estimates of 2.40 could be missed. It looks as though CEDC has no more room to grow in Poland. Again, that is the case the short sellers are making. The management is great and the stock is historically really cheap. Would look to set stop loss at 29. Target 55 july 2007

PLMD: 35.84 Rating: Sell Hedge

Plmd technically is setup similar to asei and we all know what happened after their earnings report. Down almost 20 points in two days. I'd short PlMD and buy the June 40 call options to hedge your position. Earnings out Thursday.

MEE 37.80 Rating: Strong Buy

Mee technically had a great reversal day. Coal is king. One year target 55-60.

ZIXI Watchlist Price 1.00 Rating Hold/Sell

Zixi: currently down to 1.00 Company has been on the edge of growth year after year. Each year they dissapoint. This one should definitely be a added to a watchlist. Would look for a huge down day before entering. Still think this stock could hit .50 before it rebounds. But would definitely buy at those levels. Would only enter this stock as a trade below .60 cents short term only.

THLD Intraday up 4.39.

THLD broke out above four only to close down 4% on heavy volume. We recommended this as a value play at 3.34 and still would rate this a strong buy. Until the stock approaches $7.00, I would throw the charts out the door.